Cannara Biotech Inc. (LOVFF) Financials
LOVFF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Feb. 28, 2026 | 133.2 million | 45.1 million |
| Nov. 30, 2025 | 124.4 million | 44.8 million |
| Aug. 31, 2025 | 122.7 million | 48.3 million |
| May 31, 2025 | 123.8 million | 52.0 million |
LOVFF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Feb. 28, 2026 | -209825 | 799523 |
| Nov. 30, 2025 | 2.4 million | 1.2 million |
| Aug. 31, 2025 | 990334 | 228419 |
| May 31, 2025 | 8.5 million | 191225 |
LOVFF Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| Feb. 28, 2026 | 1.2 million |
| Nov. 30, 2025 | 744121 |
| Aug. 31, 2025 | 2.4 million |
| May 31, 2025 | 3.0 million |
LOVFF Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Feb. 28, 2026 | 16.1 million | 18.5 million | 180914 |
| Nov. 30, 2025 | 11.8 million | 18.3 million | 230905 |
| Aug. 31, 2025 | 10.4 million | 20.5 million | 288087 |
| May 31, 2025 | 10.5 million | 24.7 million | 341264 |
LOVFF Shares Outstanding
LOVFF Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Feb. 28, 2026 | 2.4 million | 293667 | 5.6 million | 2.1 million |
| Nov. 30, 2025 | 3.3 million | 205759 | 5.7 million | 1.9 million |
| Aug. 31, 2025 | 1.1 million | 139075 | 4.6 million | 2.0 million |
| May 31, 2025 | 1.6 million | 128766 | 4.2 million | 1.9 million |
LOVFF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Feb. 28, 2026 | 19.9 million | 11.4 million |
| Nov. 30, 2025 | 21.6 million | 13.5 million |
| Aug. 31, 2025 | 20.8 million | 11.7 million |
| May 31, 2025 | 19.9 million | 10.5 million |
LOVFF
Price: $1.35
52 week price:
Earnings Per Share: 0.09 USD
P/E Ratio: 15
Exchange: OQB
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market Capitalization: 123.5 million